Experienced in Thrombocytopenia

Dr. Juan D. Cuevas

Oncology | Hematology
St Louis Cancer Care Llp
3440 De Paul Ln, Suite 201, 
Bridgeton, MO 
Accepting New Patients
Experienced in Thrombocytopenia
St Louis Cancer Care Llp
3440 De Paul Ln, Suite 201, 
Bridgeton, MO 
OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

Juan Cuevas is an Oncologist and a Hematologist in Bridgeton, Missouri. Dr. Cuevas is rated as an Experienced provider by MediFind in the treatment of Thrombocytopenia. His top areas of expertise are Breast Cancer, Paget Disease of the Breast, Pleuropulmonary Blastoma, and HER-2 Positive Breast Cancer. Dr. Cuevas is currently accepting new patients.

His clinical research consists of co-authoring 1 peer reviewed article and participating in 8 clinical trials. MediFind looks at clinical research from the past 15 years.

Specialties
Oncology
Hematology
Licenses
Internal Medicine in MO
Hospital Affiliations
Ssm St Joseph Health Center
Ssm Health Depaul Hospital St Louis
St Lukes Hospital
Languages Spoken
English
Portuguese
Spanish
Gender
Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Anthem
  • EPO
  • HMO
  • POS
  • PPO
Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
Cigna
  • EPO
  • HMO
  • PPO
Dean Health
  • EPO
  • HMO
  • POS
  • PPO
Essence Healthcare
  • INSURANCE PLAN
  • MEDICARE MAPD
Health Care Services Corporation
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
  • PPO
Home State Health
  • EPO
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Managed Medicaid
  • OTHER MANAGED MEDICAID
Medica
  • EPO
  • HMO
  • PPO
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
Oscar
  • EPO
  • HMO
  • PPO
TeamCare
  • OTHER COMMERCIAL
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 11 Less Insurance Carriers -

Locations

ST LOUIS CANCER CARE LLP
3440 De Paul Ln, Suite 201, Bridgeton, MO 63044

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

7 Clinical Trials

Phase 2 Study of Carboplatin, Etoposide, and Atezolizumab With or Without Trilaciclib in Patients With Untreated Extensive-Stage Small Cell Lung Cancer (SCLC)
Phase 2 Study of Carboplatin, Etoposide, and Atezolizumab With or Without Trilaciclib in Patients With Untreated Extensive-Stage Small Cell Lung Cancer (SCLC)
Enrollment Status: Completed
Publish Date: September 25, 2025
Intervention Type: Drug
Study Drugs: Trilaciclib, Carboplatin, Etoposide, Atezolizumab
Study Phase: Phase 2
A Phase II Single-arm Trial to Investigate Tepotinib in Advanced (Locally Advanced or Metastatic) Non-small Cell Lung Cancer With METex14 Skipping Alterations or MET Amplification (VISION)
A Phase II Single-arm Trial to Investigate Tepotinib in Advanced (Locally Advanced or Metastatic) Non-small Cell Lung Cancer With METex14 Skipping Alterations or MET Amplification (VISION)
Enrollment Status: Active_not_recruiting
Publish Date: August 14, 2025
Intervention Type: Drug
Study Drug: Tepotinib
Study Phase: Phase 2
A Phase II, Two-arm Study to Investigate Tepotinib Combined With Osimertinib in MET Amplified, Advanced or Metastatic NSCLC Harboring Activating EGFR Mutations and Having Acquired Resistance to Prior Osimertinib Therapy (INSIGHT 2)
A Phase II, Two-arm Study to Investigate Tepotinib Combined With Osimertinib in MET Amplified, Advanced or Metastatic NSCLC Harboring Activating EGFR Mutations and Having Acquired Resistance to Prior Osimertinib Therapy (INSIGHT 2)
Enrollment Status: Active_not_recruiting
Publish Date: February 20, 2025
Intervention Type: Drug
Study Drugs: Tepotinib, Osimertinib
Study Phase: Phase 2
PRESERVE 1: A Phase 3 Randomized, Double-blind Trial of Trilaciclib Versus Placebo in Patients Receiving FOLFOXIRI/Bevacizumab for Metastatic Colorectal Cancer
PRESERVE 1: A Phase 3 Randomized, Double-blind Trial of Trilaciclib Versus Placebo in Patients Receiving FOLFOXIRI/Bevacizumab for Metastatic Colorectal Cancer
Enrollment Status: Terminated
Publish Date: November 26, 2024
Intervention Type: Drug
Study Drug: Trilaciclib
Study Phase: Phase 3
A Phase 2 Randomized, Double-blind, Clinical Trial of Trilaciclib Versus Placebo in Patients With Metastatic Non-Small Cell Lung Cancer (NSCLC) Treated With Docetaxel in the 2nd/3rd Line Setting (PRESERVE 4)
A Phase 2 Randomized, Double-blind, Clinical Trial of Trilaciclib Versus Placebo in Patients With Metastatic Non-Small Cell Lung Cancer (NSCLC) Treated With Docetaxel in the 2nd/3rd Line Setting (PRESERVE 4)
Enrollment Status: Terminated
Publish Date: April 14, 2023
Intervention Type: Drug
Study Drugs: Trilaciclib, Docetaxel
Study Phase: Phase 2
Role of Circulating Tumor DNA (ctDNA) From LIquid Biopsy in Early Stage NSCLC Resected Lung Tumor Investigation
Role of Circulating Tumor DNA (ctDNA) From LIquid Biopsy in Early Stage NSCLC Resected Lung Tumor Investigation
Enrollment Status: Terminated
Publish Date: November 19, 2020
Intervention Type: Other
Randomized Study of AM0010 in Combination With FOLFOX Compared to FOLFOX Alone as Second-line Tx in Pts With Metastatic Pancreatic Cancer That Has Progressed During or Following a First-Line Gemcitabine Containing Regimen
Randomized Study of AM0010 in Combination With FOLFOX Compared to FOLFOX Alone as Second-line Tx in Pts With Metastatic Pancreatic Cancer That Has Progressed During or Following a First-Line Gemcitabine Containing Regimen
Enrollment Status: Completed
Publish Date: October 19, 2020
Intervention Type: Biological, Drug
Study Phase: Phase 3
View 6 Less Clinical Trials

1 Total Publications

Measures of functional status in older patients treated with palbociclib for advanced breast cancer.
Measures of functional status in older patients treated with palbociclib for advanced breast cancer.
Journal: Journal of geriatric oncology
Published: March 23, 2023
Similar Doctors
Distinguished in Thrombocytopenia
Dr. Justin D. Floyd
Oncology | Hematology
Distinguished in Thrombocytopenia
Dr. Justin D. Floyd
Oncology | Hematology

Cancer Care Specialists Of Central Illinois Sc

321 Regency Park, Suite 100, 
O Fallon, IL 
 (29.8 miles away)
618-416-7970
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Justin Floyd is an Oncologist and a Hematologist in O Fallon, Illinois. Dr. Floyd is rated as a Distinguished provider by MediFind in the treatment of Thrombocytopenia. His top areas of expertise are Lung Cancer, Pleuropulmonary Blastoma, Small Cell Lung Cancer (SCLC), and Colorectal Cancer. Dr. Floyd is currently accepting new patients.

Advanced in Thrombocytopenia
Dr. Elaine M. Majerus
Hematology | Oncology
Advanced in Thrombocytopenia
Dr. Elaine M. Majerus
Hematology | Oncology

Washington University

1 Barnes Jewish Hospital Plz, 
Saint Louis, MO 
 (12.1 miles away)
314-747-3000
Languages Spoken:
English
See accepted insurances
Accepting New Patients

Elaine Majerus is a Hematologist and an Oncologist in Saint Louis, Missouri. Dr. Majerus is rated as a Distinguished provider by MediFind in the treatment of Thrombocytopenia. Her top areas of expertise are Anemia, Monoclonal Gammopathy of Undetermined Significance (MGUS), Schnitzler Syndrome, and Hemophilia A. Dr. Majerus is currently accepting new patients.

Distinguished in Thrombocytopenia
Dr. Morey Blinder
Hematology | Transfusion Medicine
Distinguished in Thrombocytopenia
Dr. Morey Blinder
Hematology | Transfusion Medicine

Washington University

1 Barnes Jewish Hospital Plz, 
Saint Louis, MO 
 (12.1 miles away)
314-747-3000
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Morey Blinder is a Hematologist and a Transfusion Medicine provider in Saint Louis, Missouri. Dr. Blinder is rated as a Distinguished provider by MediFind in the treatment of Thrombocytopenia. His top areas of expertise are Sickle Cell Disease, Hemoglobin SC Disease, Acute Myeloblastic Leukemia without Maturation, Acute Myeloid Leukemia (AML), and Thrombectomy.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Cuevas's expertise for a condition
ConditionClose
    View All 9 Advanced Conditions
    View All 94 Experienced Conditions
    Want to save this doctor for later?
    Sign Up
    Is this your doctor?
    Find A Second Opinion
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile